|
GB202006236D0
|
|
New treatment
|
|
GB202002786D0
|
|
Liquid pharmaceutical composition
|
|
GB201911517D0
|
|
Pharmaceutical composition
|
|
GB201816447D0
|
|
Liquid pharmaceutical composition comprising RPL554 and HFA-134A
|
|
GB201613054D0
|
|
New compound and process
|
|
GB201602784D0
|
|
New treatment of CFTR-related disorders
|
|
HUE045303T2
|
|
Liquid inhalation formulation comprising rpl554
|
|
CA2948620A1
|
|
New treatment
|
|
GB201504662D0
|
|
Formulation
|
|
GB201502260D0
|
|
Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
|
|
GB201417719D0
|
|
New treatment
|
|
GB201416274D0
|
|
Formulation
|
|
GB201408384D0
|
|
New treatment
|
|
HUE037275T2
|
|
Drug combination
|
|
WO2014037726A1
|
|
Liquid pharmaceutical compositions
|
|
WO2014037727A1
|
|
Carcainium salts
|
|
GB201304501D0
|
|
Liquid pharmaceutical compositions
|
|
MY157432A
|
|
Crystalline form of pyrimido [6, 1-a] isoquinolin-4-one compound
|
